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Abstract
In mice there are clear individual differences in the development of behavioral sensitization to ethanol, a progressive
potentiation of its psychomotor stimulant effect. Variability in the behavioral responses to ethanol has been associated with
alcohol preference. Here we investigated if the functional hyperresponsiveness of D1 receptors observed in ethanol
sensitized mice leads to an increased activation of DARPP-32, a central regulatory protein in medium spiny neurons, in the
nucleus accumbens - a brain region known to play a role in drug reinforcement. Swiss Webster mice received ethanol (2.2 g/
kg/day) or saline i.p. administrations for 21 days and were weekly evaluated regarding their locomotor activity. From those
treated with ethanol, the 33% with the highest levels of locomotor activity were classified as ‘‘sensitized’’ and the 33% with
the lowest levels as "non-sensitized’’. The latter presented similar locomotor levels to those of saline-treated mice. Different
subgroups of mice received intra-accumbens administrations of saline and, 48 h later, SKF-38393, D1 receptor agonist 0.1 or
1 mg/side. Indeed, sensitized mice presented functional hyperresponsiveness of D1 receptors in the accumbens. Two weeks
following the ethanol treatment, other subgroups received systemic saline or SKF 10 mg/kg, 20 min before the euthanasia.
The nucleus accumbens were dissected for the Western Blot analyses of total DARPP-32 and phospho-Thr34-DARPP-32
expression. D1 receptor activation induced higher phospho-Thr34-DARPP-32 expression in sensitized mice than in non-
sensitized or saline. The functionally hyperresponsiveness of D1 receptors in the nucleus accumbens is associated with an
increased phospho-Thr34-DARPP-32 expression after D1 receptor activation. These data suggest that an enduring increase
in the sensitivity of the dopamine D1 receptor intracellular pathway sensitivity represents a neurobiological correlate
associated with the development of locomotor sensitization to ethanol.
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Introduction
Although alcoholism is a worldwide problem resulting in
millions of deaths_ENREF_1, only a small percentage of alcohol
users become addicted [1]. Many studies have documented a
marked heterogeneity in behavioral responsiveness to ethanol
[2,3,4]. Psychomotor sensitization to ethanol, a form of drug-
dependent behavioral adaptation (defined as a progressive increase
in psychomotor stimulant response with repeated drug exposure),
has been suggested as a behavioral marker for alcohol preference
and/or abuse liability in both animals [5,6] and humans [7]. Our
previous studies identified significant individual differences in the
development of behavioral sensitization to ethanol in outbred
Swiss Albino Webster mice. While a subgroup of ethanol-treated
mice showed a robust sensitization (sensitized group), others, in
spite of receiving identical ethanol treatment, failed to show this
drug-induced behavioral plasticity (non-sensitized group) and
presented similar levels of activity to a saline-treated control
group [8,9]. Variations in the development of ethanol sensitization
probably reflect individual differences in addiction vulnerability,
since sensitized mice voluntarily drink more ethanol than non-
sensitized or saline-treated control mice [10].
Drugs of abuse activate the mesolimbic dopamine reward
system, promoting increased dopamine concentrations in the
nucleus accumbens (NAc) [11,12], a brain region known to play an
important role in drug reinforcement. Neuroadaptations in the
NAc are supposed to mediate many of the behavioral changes that
underlie addiction [13]. The released dopamine can act on both
D1 and D2 subtypes of dopaminergic receptors. D1 dopamine
receptors are coupled to stimulatory G-protein that stimulates
adenylyl cyclase and activates cyclic AMP-dependent protein
kinases such as the protein kinase A (PKA). PKA increases the
phosphorylation of dopamine- and cAMP-regulated phosphopro-
tein of 32 kDa (DARPP-32) at threonine (Thr) 34 residue
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(phospho-Thr34-DARPP-32). DARPP-32 is located in neurons
containing dopamine receptors and plays a central role in
dopaminergic [14] and glutamatergic signaling integrating the
activity of these two pathways [15]. The dysfunction of these
cellular pathways has been associated with several major
neurologic and psychiatric disorders, including drug dependence
[16].
Our previous data demonstrated that, after a long-term (two
weeks) withdrawal following a 5-day ethanol treatment, those mice
that developed sensitization showed functionally hyperresponsive
D1 receptors in the NAc [8]. In the present study, we hypothesized
that after a longer ethanol treatment (21 days), sensitized mice
should present a more preeminent locomotor hyperresponsiveness
to a D1 receptor agonist administration and that this could be
associated with increased levels of phospho-Thr34-DARPP-32 by
the activation of accumbal dopaminergic D1 receptors.
Materials and Methods
Subjects
All animal procedures were performed in accordance with the
National Institutes of Health (NIH) Principles of Laboratory
Animal Care (1985). The Committee for Ethics in Research of the
Universidade Federal de Sa˜o Paulo approved the protocol (CEP
#0455/08). All procedures implemented in this study observed
ethical criteria for minimizing the number of animals used and
their suffering. A total of 139 male Swiss Albino Webster mice
from the colony of CEDEME (Centro de Desenvolvimento de
Modelos Experimentais para Medicina e Biologia - Universidade
Federal de Sao Paulo) were housed in plastic cages
(44634616 cm) in groups of 15–20 and given free access to food
and water. Animals that underwent surgical procedures were
housed in smaller plastic cages (30619613 cm) in groups of 4 or 5
after the surgery. They were kept in a temperature-controlled
colony room (22uC61uC) with lights on between 07:00 AM and
07:00 PM. Mice were approximately 75 days old at the beginning
of each experiment.
Chronic ethanol treatment
To induce sensitization to the stimulant effects of ethanol, we
adopted previously described procedures [8,17]. To assess baseline
locomotor activity, we initially evaluated all the animals in one
15 min session without any drug treatment in Opto-Varimex
cages (Columbus Instruments, Columbus, Ohio;
47.5625.7620.5 cm), which detect locomotor activity by inter-
ruptions of horizontal photoelectric beams. We compared the
locomotor activity of the different treatment groups prior to the
experiments to control the influence of baseline reactivity on
treatment outcomes (please see Material S1). One day after
baseline assessment, mice received either saline or 2.2 g/kg of
ethanol (Synth, Sa˜o Paulo, Brazil 15% w/v) daily during 21 days.
On days 1, 7, 14 and 21 of the treatment, mice received saline or
ethanol administration and were immediately placed in the
locomotor activity cages, remaining there for 15 min. All the
procedures were performed between 12:00 PM and 05:00 PM.
According to their locomotor response on the 21st day test, the
ethanol-treated mice were sorted and classified as sensitized mice
(those whose activity levels were in the upper 33% of the
distribution) or non-sensitized (those whose activity levels were in
the lower 33% of the distribution), as described in previous studies
[8,9,18]. The intermediate group of mice was not included in the
experiments. This methodology allows studying the two extreme
profiles of behavioral response to a same drug treatment and the
possible factors involved in this individual variability.
Experiment 1 – D1 Receptor Activity on
Locomotor Behavior
Surgical procedures
After the 21-day chronic ethanol treatment, we anesthetized the
mice with xylazine (10 mg/kg in 0.01 ml/g, i.p.) and ketamine
(8 mg/kg in 0.01 ml/g, i.p.) before placing them in a stereotactic
apparatus (Model EFF-333, Insight Ltd., Brazil). We implanted
bilateral stainless steel guide cannulae (23 gauge and 8.0 mm in
length) 2.5 mm above the nucleus accumbens (NAc) (AP+1.2 mm,
ML61.0 mm, DV - 2.0 mm from bregma [19]. The guide
cannulae were anchored to the skull with two additional stainless
steel screws and dental cement. At the end of the surgery, stainless
steel wire stylets were inserted into the guide cannulae to prevent
occlusion. The mice were allowed to recover for 5–10 days. In the
challenge tests, drugs were infused bilaterally into the NAc using
10.5-mm-long injection cannulae (30 gauge) that extended an
additional 2.5 mm below the guide cannulae tips. The injectors
were connected via polyethylene microbore tubing to 10- ml
Hamilton microsyringes mounted on a micro-drive pump (Model
EFF-311, Insight Ltd., Brazil). Each microinjection was performed
in a volume of 0.2 ml per side at a rate of 0.2 ml/min. Thirty
seconds after the infusion, the injection cannulae were removed,
and the animals were placed in the activity cages.
Challenges
After the chronic treatment with ethanol or saline, different
subgroups of mice of saline, non-sensitized and sensitized groups
(one group for each dose of D1 receptor agonist) were initially
challenged with intra-NAc administration of saline and, 48 h later,
submitted to a second challenge with 0.1 or 1 mg/side of SKF (D1
receptor agonist SKF-38393 hydrochloride, Sigma-Aldrich, Bra-
zil), in order to assess the D1 receptor function in sensitized or
non-sensitized mice to the stimulant effects of ethanol.
Histology
After the challenges, the mice were anesthetized with a high
dose of ketamine and euthanized by decapitation. Their brains
were removed, frozen on dry ice and stored at 280uC. We
analyzed the placements of the injection sites, according to the
atlas of Paxinos and Franklin [19], by histological examination of
frozen 40- mm coronal brain sections stained with cresyl violet.
Only the data from mice whose cannulae placements were correct
(see Figure 1) were included in the analysis. We lost eleven mice
from the saline group, eighteen mice from the non-sensitized
group and seventeen mice from the sensitized group due to
incorrect placements or other problems during the surgery.
Experiment 2 – D1 Receptor Activity on
Phosphorylation of DARPP-32
Western blot
Fourteen days after the chronic ethanol treatment protocol,
mice from saline, non-sensitized and sensitized groups received an
i.p. administration of 10 mg/kg SKF and, 20 min later, they were
euthanized by decapitation. Brains were quickly removed, frozen
over dry ice and stored at 280uC. The nucleus accumbens
(bregma 1.94 to 0.62 mm) were punched from the brain slices
sectioned in the coronal plane on a Hacker-Bright cryostat at 2
20uC, according to the Paxinos and Franklin mouse Atlas [19].
Total protein extract was prepared using lysis buffer containing
50 mM Tris-HCl (pH 7.4), 150 mM NaCl, 1% Triton x-100,
0.1% SDS, 1 mM EDTA, and 1% sodium deoxycholate. The
protein concentration was determined using the Bio-Rad Protein
EtOH Sensitization Increases D1 DARPP-32 Signaling
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Figure 1. Diagram of approximate microinjections hits. The crosses (+) represent the positions of microinjections in both sides of the Nucleus
Accumbens considered correct. The basic diagram is a modified representation of Paxinos and Franklin (2004) atlas.
doi:10.1371/journal.pone.0098296.g001
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Assay – Hercules, CA [20]. 50 ı`g proteins were separated by 10%
SDS-polyacrylamide gel electrophoresis and transferred to a
nitrocellulose membrane at 100 volts for 60 min. The blots were
blocked with 1% bovine serum albumin in TBST (10 mM Tris,
pH 7.5, 100 mM NaCl and 0.1% Tween 20) for 1 hour at room
temperature and then incubated with the rabbit polyclonal
antibody against DARPP-32 (Abcam, Cambridge, MA) and
phospho-DARPP-32 (Santa Cruz Biotechnology, Santa Cruz,
CA) in 1:1000 dilution in 1% bovine serum albumin/TBST
overnight at 4uC. Excess of primary antibody was removed with
three washes with TBST prior to 1 hour incubation at room
temperature with goat anti-rabbit secondary antibody conjugated
with alkaline phosphatase (Santa Cruz Biotechnology, Santa Cruz,
CA) in 1:5000 dilution in 5% nonfat dry milk/TBST for 1 hour.
Membrane was incubated for 5 min in substrate for the detection
of the alkaline phosphatase (Sigma Fast BCIP/NBT - Sigma
Aldrich Inc. St. Louis). The bands were analyzed and quantitation
was done using AlphaEaseFC Software (Alpha Innotech, San
Leandro, CA) with aˆ-tubulin as an endogenous reference. The
assay was conducted in duplicate for each sample. Samples of total
DARPP-32 and phospho-DARPP-32 were harvested separated.
Data analyses
For each experiment, the locomotor activity counts recorded
during the treatment or challenge tests were evaluated by two-way
analysis of variance (ANOVA) for repeated measures, with group
(saline, sensitized or non-sensitized mice) as the independent factor
and the days of the tests, time during the challenge or different
challenges as the repeated measure factors. The comparison of the
levels of expression of total DARPP-32, phospho-Thr34-DARPP-
32 and phospho-Thr34-DARPP-32/total DARPP-32 among
saline, sensitized or non-sensitized mice was made by one-way
ANOVAs. Newman-Keuls tests for multiple comparisons were
used for post-hoc analyses. The level of significance was set at 5%
for all analyses. All analyses were made using the software
Statistica version 10 (Statsoft Inc, 2011).
Results
Development of behavioral sensitization to ethanol
Figure 2A-B shows the development of behavioral sensitization
to the stimulant effects of ethanol in the two cohorts of mice that
received 0.1 mg/side or 1.0 mg/side of SKF in the pharmacolog-
ical phase of Experiment 1. In both cohorts, two clearly different
profiles of locomotor activity were observed: a group that
Figure 2. There is clear individual variability to the development of sensitization to ethanol. Locomotor activity for 15 min (means 6
S.E.M.) of mice treated with saline or 2.2 g/kg ethanol i.p. (classified as non-sensitized (nsens) or sensitized (sens) based on their locomotor activity in
the 21st day test) in the tests performed on days 1, 7, 14 and 21. (A) Cohort of mice (saline, n = 8; nsens, n = 5; sens, n = 8) that received the lower dose
of SKF during the challenge phase. (B) Cohort of mice (saline, n = 11; nsens, n = 6; sens, n = 7) that received the higher dose of SKF during the
challenge phase. (C) Cohort of mice (saline, n = 8; nsens, n = 8; sens, n = 9) that was designed for DARPP-32 measures after saline administration. (D)
Cohort of mice (saline, n = 6; nsens, n = 7; sens, n = 7) that was designed for DARPP-32 measures after SKF administration. * indicates significantly
higher activity levels than those presented by the saline and nsens groups during the same test (p,0.05) and when compared to their own levels in
test 1 (p,0.05).
doi:10.1371/journal.pone.0098296.g002
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developed a clear sensitization after the tests (sensitized mice) and
another group that presented low activity levels (non-sensitized
mice). The latter presented similar levels to those observed in the
control (saline) group. In Figure 2A, a repeated measures ANOVA
revealed significant effects of group (F(2,15) = 72.46; p,0.001), test
(F(3,45) = 10.21; p,0.001) and group-test interaction factors
(F(6,45) = 20.23; p,0.001). The sensitized group of mice showed
robust behavioral sensitization with a progressive increase in the
activity levels during the ethanol treatment (p,0.05). They
presented significantly higher activity levels on tests 14 and 21
than on tests 1 and 7; and higher levels than those from saline and
non-sensitized mice on tests 7, 14 and 21 (p,0.05). The non-
sensitized mice did not display progressive locomotor stimulation
but similar activity levels to those observed in the control group. It
is noteworthy that there were no significant differences in the acute
(test 1) locomotor activity levels among saline, sensitized and non-
sensitized groups. Similar results were observed as regards the
cohort that would receive 1.0 mg/side of SKF as shown in
Figure 2B (repeated measures ANOVA: effects of group
F(2,21) = 50.65; p,0.001, test F(3,63) = 32.24; p,0.001 and
group-test interaction factors F(6,63) = 29.34; p,0.001).
Figure 2C–D shows the development of behavioral sensitization
to the stimulant effects of ethanol in mice that received saline or
SKF-38393 prior to the measures of expression of DARPP-32 and
phosphoDARPP-32. Similar results were observed for both groups
of mice which received saline or SKF-38393 administration prior
to the euthanasia (repeated measures ANOVA: Figure 2C effects
of group F(2,44) = 27.73; p,0.001, test F(3,66) = 28.11; p,0.001
and group-test interaction factors F(6,66) = 12.17; p,0.001.
Figure 2D shows the effects of group F(2,19) = 52.28; p,0.001,
test F(3,57) = 15.33; p,0.001 and group-test interaction factors
F(6,57) = 7.04; p,0.001). After post-hoc analyses, we observed
similar results to those described in the previous experiment.
It is important to consider that the development of behavioral
sensitization could be associated with the initial baseline locomotor
response to novel environment. To address whether the baseline
levels could predict which mice would be categorized as sensitized
versus non-sensitized, we retrospectively analyzed the baseline
(novelty) data of the three groups of animals: saline, non-sensitized
and sensitized mice in the four cohorts used in the present study
(Material S1). No differences were observed in the locomotor levels
among the groups when the animals were exposed to the
locomotor activity cage for the very first time (Figure S1). This
indicates that the baseline locomotor activity levels do not predict
the development of behavioral sensitization to the stimulant effect
of ethanol.
Functionally hyperresponsive D1 receptors in ethanol
sensitized mice
The pharmacological phase of this study was performed to
compare sensitized and non-sensitized mice regarding their D1
dopamine receptors responsiveness to intra-NAc administration of
SKF in different doses. Figure 3A–B shows the locomotor activity
levels of saline, non-sensitized and sensitized groups that received
saline and, 48 h later, 0.1 mg/side of SKF. We performed
repeated measures ANOVA for each challenge, considering group
as the independent factor and the locomotor activity along with
time as the dependent variable. In the saline challenge (Figure 3A),
the ANOVA revealed significant effect of the time factor
(F(15,240) = 20.76; p,0.001), but not of the group
(F(2,16) = 1.49) or the group-time interaction (F(30,240) = 1.06)
factors. We observed a decrease in the locomotor activity levels
during time (p,0.05). In the 0.1 mg/side SKF challenge
(Figure 3B), the ANOVA revealed significant effect of time factor
(F(15,240) = 12.64; p,0.001), but no effect of group factor
(F(2,16) = 1.69) or group-time interaction (F(30,240) = 1.43). De-
spite no group effect, we observed a slight increase in the
locomotor activity of the sensitized group during the first 15
minutes after the agonist administration. To analyze this effect, we
compared the total locomotor activity levels during the first 15
minutes after saline and 0.1 mg/side SKF challenges (see
Figure 3C). The ANOVA revealed significant effect of challenge
factor (F(1,16) = 26.25; p,0.001) but not of group factor
(F(2,16) = 2.81; p = 0.09) or group-challenge interaction
(F(2,16) = 3.06; p = 0.07). The unprotected post-hoc analyses
revealed that sensitized mice showed higher levels of locomotor
activity after 0.1 mg/side SKF administration than after saline
challenge. Besides, in the 0.1 mg/side SKF challenge, sensitized
mice showed higher levels of locomotor activity than the other
groups.
Figure 3D–F shows the locomotor activity levels of saline, non-
sensitized and sensitized groups that received saline and, 48h later,
1.0 mg/side of SKF. In the saline challenge (Figure 3D), the
ANOVA did not detect the factor group as significant
(F(2,21) = 3.56), but revealed significant effect of time
(F(11,231) = 2,09; p,0,05) and no group-time interaction
(F(22,231) = 1,3). We observed a decrease in the locomotor activity
during time (p,0.05). In the 1.0 mg/side SKF challenge
(Figure 3E), the ANOVA revealed significant effect of the time
factor (F(11,231) = 12.13; p,0.001), group (F(2,21) = 6.07), but no
group-time interaction (F(22,231) = 1.26) factors. The close ana-
lyze of the graph suggests that the sensitized group had higher
stimulant effect than the others. Because of this, the total
locomotor activity levels during the first 60 minutes after saline
or 1.0 mg/side SKF challenges are presented in Figure 3F. The
ANOVA revealed significant effect of challenge factor
(F(1,21) = 41.79; p,0.001), group (F(2,21) = 6.19; p,0.05) and
group-challenge interaction (F(2,16) = 5.67; p,0.05) factors. The
post-hoc analyses revealed that after 1.0 mg/side SKF intra-NAc
administration, sensitized mice showed higher levels of locomotor
activity than in the saline challenge and higher levels than the
other two groups: saline and non-sensitized.
Increased phosphorylation of DARPP-32 in ethanol
sensitized mice
Figure 4 shows the protein expression (% of controls) of total
DARPP-32, phospho-Thr34-DARPP-32 and phospho-Thr34-
DARPP-32/total DARPP-32 in the NAc, 14 days after saline or
ethanol treatment. No differences were observed among the three
groups in the total DARPP-32 expression after saline administra-
tion (Figure 4A; F(2,22) = 2.12). However, non-sensitized and
sensitized groups had lower levels of phospho-Thr34-DARPP-32
expression than saline-treated controls (Figure 4A, F(2,22) = 54.00;
p,0.001). We observed lower phospho-Thr34-DARPP-32/total
DARPP-32 expression in non-sensitized and sensitized groups
when compared to saline group (F(2,22) = 197.58; p,0.001).
As seen in Figure 4B, after SKF administration the non-
sensitized and sensitized groups showed higher levels of expression
of DARPP-32 in the NAc when compared to the levels of saline
treated mice that have previously received SKF (p,0.05). The
dopaminergic D1 agonist administration induced higher levels of
phospho-Thr34-DARPP-32 expression in the sensitized group
than in the saline or non-sensitized groups (F(2,17) = 173.62; p,
0.001). Besides, the non-sensitized group showed higher levels of
phospho-Thr34-DARPP-32 expression than the saline controls
(p,0.05). After D1 agonist administration, we observed that
phospho-Thr34-DARPP-32/total DARPP-32 expression was
EtOH Sensitization Increases D1 DARPP-32 Signaling
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higher in the sensitized mice than in the non-sensitized or saline
mice (F(2,17) = 235.35; p,0.001).
Discussion
We demonstrated an important association between the
variability in behavioral sensitization to the stimulant effect of
ethanol and the functionality of dopamine D1 receptors and its
intra-cellular cascade pathway. After a two-week drug-free period,
following a 21-day ethanol treatment, those mice that had
developed high levels of sensitization showed an increased
locomotor response and an increased phosphorylation of
DARPP-32 in NAc after the administration of a D1 receptor
agonist. It is important to note that these effects were not observed
in all mice submitted to the 21-day ethanol treatment. In spite of
receiving the same amount of ethanol, non-sensitized mice did not
present alterations in the functionality of the accumbal D1
receptors when compared to controls.
Repeated exposure to drugs of abuse, such as ethanol,
progressively increases their psychomotor stimulant effects, a
phenomenon known as behavioral sensitization [13,21,22]. Some
authors have proposed that sensitization to drugs of abuse can be
used as an indirect measure of the neural adaptations related to the
transition from controlled, casual use to compulsive drug use and
addiction [23,24]. Steketee and Kalivas consider that there is
similarity between the neural circuitry and the drug-induced
neurochemical changes involved in the process of sensitization and
reinstatement of drug use. As regards drug use and addiction,
there is important variability in the behavioral responses to
chronic drug treatment [25]. As demonstrated in previous studies,
outbred Swiss Albino mouse strain show significant inter-
individual variability in the development of behavioral sensitiza-
Figure 3. D1 receptor agonist induced hyperresponsive locomotion in sensitized mice. Locomotor activity (means + S.E.M.) of the saline,
sens and nsens in the challenges with intra-NAc administration of saline and SKF-38393 at 0.1 or 1 mg/side. Each challenge was performed 48 h after
the previous one. (A) Locomotor activity 20 min before and 60 min after saline intra-NAc administration of saline (n = 8), nsens (n = 5) and sens (n = 8)
groups. (B) Locomotor activity 20 min before and 60 min after SKF 0.1 mg/side intra-NAc administration of saline (n = 8), nsens (n = 5) and sens (n = 8)
groups, 48 h after the saline challenge (A). (C) Locomotor activity during 15 min (gray backgrounds in figures A and B), after intra-NAc administration
of saline and SKF 0.1 mg/side. (D) Locomotor activity 20 min before and 60 min after saline intra-NAc administration of saline (n = 11), nsens (n = 6)
and sens (n = 7) groups. (E) Locomotor activity 20 min before and 60 min after SKF 1 mg/side intra-NAc administration of saline (n = 11), nsens (n = 6)
and sens (n = 7) groups, 48 h after the saline challenge (D). (F) Locomotor activity during 60 min (gray backgrounds in figures D and E), after intra-
NAc administration of saline and SKF 1 mg/side. * indicates significantly higher activity levels than those of the saline and nsens mice and higher
locomotor activity levels than their own levels in the saline challenge (p,0.05).
doi:10.1371/journal.pone.0098296.g003
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tion to the stimulant effect of ethanol [8,9,17,18,26,27]. We
demonstrated that after two weeks of a drug-free period, the
sensitized, but not the non-sensitized mice, consumed ethanol in a
significantly higher amount than the saline controls [10].
Considering the above-mentioned findings, we hypothesize that
sensitized mice could be more vulnerable to alcohol addiction.
Since the neuroadaptations observed after ethanol treatment may
be associated with an increased vulnerability to addiction or
relapse, it is important to understand their association with the
variability in the behavioral response to ethanol treatment.
The increase of dopamine release in NAc observed after ethanol
administration [28] may be potentiated by chronic treatment.
After a 24-hour withdrawal from ethanol chronic treatment, there
is no difference in the D1 receptor binding among sensitized, non-
sensitized and saline groups [18]. However, it is possible that
neural changes may counterpoise the lack of dopamine activation
after a long-term withdrawal. In a previous study, we demon-
strated that, after a two-week withdrawal period which followed a
5-day ethanol treatment, sensitized mice presented functionally
hyper responsive D1 receptors in the NAc [8]. The present data
corroborated and extended this conclusion, pointing out that a
longer ethanol treatment (21 days) may potentiate the D1 receptor
neural adaptation. Both doses of the D1 receptor agonist, when
administered into the NAc, induced a more robust increase of the
locomotor activity in sensitized mice than in non-sensitized or
saline ones. We have also demonstrated the presence of significant
hyperfunctional accumbal D2 receptors in sensitized mice after
two weeks of withdrawal from the ethanol treatment [27]. We
could consider the hyperfunctionality of the dopaminergic
receptors in the nucleus accumbens is a response that counter-
poised a hypodopaminergia syndrome associated with ethanol
long-term withdrawal. While the hypodopaminergia may contrib-
ute to relapse, the hyperfunctionality of dopaminergic receptors
seems to be associated with the increased behavioral response to
drugs.
The DARPP-32 activity seems to be an important factor in the
ethanol reinforcement properties, since DARPP-32 knock-out
mice drank less ethanol, did not develop conditioned place
preference and had increased sensitivity to the ethanol stimulant
effect [29]. Besides, DARPP-32 phosphorilation is regulated by
ethanol [30] and differences in the regulation of this molecule
contribute to different ethanol drinking patterns in rats [31]. Here
we demonstrated that after a withdrawal period following a
chronic ethanol treatment, sensitized and non-sensitized mice
presented lower levels of phospho-Thr34-DARPP-32 expression
than saline treated controls, which may indicate low activity of
endogenous dopamine in animals pre-treated with ethanol.
However, after the D1 receptor agonist administration, ethanol
sensitized and non-sensitized mice did present higher levels of
DARPP-32 than the saline control group that also received D1
agonist administration. The interpretation of these data is not
obvious considering the specific transcriptional mechanisms that
Figure 4. D1 receptor agonist induced accumbal DARPP-32 hyperphosphorylation in sensitized mice. (A) Protein expression of total
DARPP-32, phospho-Thr34-DARPP-32 and phospho-Thr34-DARPP-32/total DARPP-32 in the NAc in saline (n = 8), nsens (n = 8) and sens (n = 9) groups,
20 min after i.p. saline administration. (B) Protein expression of total DARPP-32, phospho-Thr34-DARPP-32 and phospho-Thr34-DARPP-32/total
DARPP-32 in the NAc in saline (n = 6), nsens (n = 7) and sens (n = 7) groups, 20 min after 10 mg/kg i.p. SKF-38393 administration. * indicates
significantly higher levels than saline and nsens groups (p,0.05). + indicates significantly lower levels than saline group (p,0.05). # indicates
significantly higher levels than saline and nsens groups (p,0.05).
doi:10.1371/journal.pone.0098296.g004
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regulate striatal DARPP-32 expression remain enigmatic. It’s
known, however, that some factors can modulate DARPP-32
transcription. We may speculate that in ethanol-treated mice these
mechanisms could be hypersensitive and mediate DARPP-32
expression after the D1 agonist administration only in those mice
that had previously received chronic ethanol treatment. We also
observed that sensitized mice had higher levels of phospho-Thr34-
DARPP-32 expression than non-sensitized or saline ones. These
results corroborate the assumption that DARPP-32 plays a key
role in the development of D1 receptors involved in motor
stimulatory effects [32]. Therefore, the locomotor hyperespon-
siveness to the accumbal direct-acting D1 receptor agonist
observed in sensitized mice seems to be associated with the
increase in DARPP-32 phosphorilation at threonine 34.
Phospho-Thr34-DARPP-32 is a potent inhibitor of protein
phosphastase -1 (PP-1). This cascade increases the phosphorylation
of the major subunit of the glutamatergic NMDA receptor, NR1
[15,33]. As a consequence, the activation of D1 receptors increases
the phosphorylation of NMDA receptors through DARPP-32
pathway. It was demonstrated that the phosphorylation of the
NR1 subunit of NMDA receptors strongly decreases the acute
ethanol inhibition of NMDA receptors [30]. However, after a
long-term withdrawal from chronic ethanol treatment, diverse
neuroadaptations in NMDA receptors can be observed. We
showed that, after a two-week withdrawal period, ethanol
sensitized mice had a decrease in the functionality and expression
of NMDA receptor in the NAc [10]. The manipulation of
DARPP-32 activity could contribute to modulate the deficit in
NMDA functionality. As mention by others, DARPP-32 could be
considered a potential therapeutic target for the treatment of
alcohol or other drugs addiction, as well as for several other
psychiatric disorders [34].
The different levels of accumbal D1 receptor/DARPP-32
signaling function observed in mice with different profiles in
ethanol sensitization may be an important biomarker of behavioral
adaptations observed during ethanol administration. Indeed, non-
sensitized mice, which did not develop sensitization, did not differ
from controls in relation to D1 receptor agonist induced
locomotion and DARPP-32 phosphorylation, reinforcing the
relation between the behavioral and neuronal adaptations.
Considering that behavioral sensitization may be associated with
the reinstatement of drug use, the functionality of the intracellular
pathway of D1 receptors could contribute to the vulnerability to
relapse. A better understanding of the molecular substrates
responsible for the different levels of sensitization could unravel
new targets for the development of more effective therapies for
ethanol abuse.
Supporting Information
Figure S1 Novelty response does not predict the development of
ethanol locomotor sensitization. Locomotor activity (means 6
S.E.M.) for 15 min in the novelty test when saline, non-sensitized
(nsens) or sensitized (sens) groups were exposure to the locomotor
activity cage for the first time without drug administrations of
mice. (A) Cohort of mice (saline, n = 8; nsens, n = 5; sens, n = 8)
that received the lower dose of SKF during the challenge phase.
(B) Cohort of mice (saline, n = 11; nsens, n = 6; sens, n = 7) that
received the higher dose of SKF during the challenge phase. (C)
Cohort of mice (saline, n = 8; nsens, n = 8; sens, n = 9) that was
designed for DARPP-32 measures after saline administration. (D)
Cohort of mice (saline, n = 6; nsens, n = 7; sens, n = 7) that was
designed for DARPP-32 measures after SKF administration.
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